Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Cognito Therapeutics

< Previous 1 2 Next >
News headline image
Cognito Therapeutics OVERTURE Clinical Trial in Alzheimer's Disease Published in Frontiers in Neurology
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Announces Oral Presentation on Spectris Therapy Open-Label Study Data in Alzheimer’s Disease at AD/PD 2024
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Announces First Patient Enrolled in HOPE Biomarker Study
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Phase 2 OVERTURE Study MRI Imaging Analysis Published in Journal of Alzheimer’s Disease
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics to Present at the 35th Annual Piper Sandler Healthcare Conference
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Appoints Christian Howell as Chief Commercial Officer
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Presents Phase 2 OVERTURE Study Open-Label Extension Data Showing Safety, Adherence and Durability of Treatment Benefits Over 18 Months
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics to Present Phase 2 OVERTURE Study Open-Label Extension Data Showing Safety and Durability of Treatment Benefits Over 18 Months at CTAD 2023
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Presents New MRI Data Showing Non-Invasive Gamma Stimulation Therapy Reduces Brain Atrophy and Myelin Loss in Alzheimer’s Disease
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Announces Scientific Presentations at the Alzheimer’s Association International Conference 2023
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Announces Poster Presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Meeting
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Announces Key Medical and Technology Leadership Appointments as Late-Stage Neurotechnology Platform Advances
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Announces Gamma-Frequency Sensory Stimulation Decreases Brain Atrophy in Patients with Alzheimer’s Disease at AD/PD 2023
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer’s Disease
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Announces First Patient Enrollment in US Pivotal Study HOPE
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics to Present Clinical Data Evaluating Gamma Frequency Neuromodulation in Alzheimer’s Disease at 2022 CTAD Conference
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Announces Proprietary Gamma Sensory Stimulation for 6-Months Reduces White Matter Atrophy in Alzheimer’s Disease Patients
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Announces Data Presentations at the Alzheimer’s Association International Conference 2022
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Joins Digital Medicine Society’s (DiMe) Alzheimer's Disease and Related Dementias Project to Advance Next-Generation Clinical Measures
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics and Providence Health Plan Launch Phase 3 Study to Evaluate Disease-Modifying Therapeutic in Mild Cognitive Impairment
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Appoints Jennifer Newberger as Head of Regulatory and Compliance
From Cognito Therapeutics
Via Business Wire
News headline image
Digital Therapeutics Alliance Elects Cognito Therapeutics’ Everett Crosland to its Board of Directors
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics CEO Brent Vaughan to Speak at CODE Conference 2021
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Announces Formation of Payor Advisory Board
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2021
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Presents New Clinical Data Demonstrating Disease-Modifying Effects of Gamma Frequency Neuro-modulation on Cognitive Function and Brain Atrophy in Alzheimer’s Disease at AAIC 2021
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2021
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Appoints Gerald Chan as Chairman of the Board
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Initiates Studies in Down Syndrome Associated Alzheimer’s Disease
From Cognito Therapeutics
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.